{"schema_version":"1.0","type":"article","title":"生技人必須知道的 2026 Q2 重磅藥物","url":"https://drugnews.com.tw/articles/2026-04-16-2026-q2.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-16-2026-q2.md","lang":"zh-Hant","date":"2026-04-16","publish_at":"2026-04-16T10:30:00+08:00","updated_at":"2026-04-16","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年第二季，全球生技醫藥產業正走進一個少見的高密度催化期。若把臨床讀數、監管決策與關鍵會議節點一起看，從 4 月到 6 月前後，至少有 17 個值得緊盯的重磅資產將陸續揭曉方向；更早一步，Eli Lilly 的口服減重藥 orforglipron（Foundayo） 已在 4 月 1 日獲 …","key_points":[],"facts":[],"sections":["17 個重磅藥物，正在把 2026 年 Q2 變成生醫產業的分水嶺"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"\"Biopharma catalysts in Q2 2026 signal high-profile approval decisions and rising competition, reveals GlobalData - International Biopharmaceutical Industry\"","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"FDA Approves First New Molecular Entity Under National Priority Voucher Program","source":"FDA","date":"","url":""},{"title":"The U.S. Food and Drug Administration today approved Foundayo (orforglipron) marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program.","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"![Dcard 原圖：生技人必須知道的 2026 Q2 重磅藥物（圖 3）](images/dcard-03.png","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：生技人必須知道的 2026 Q2 重磅藥物（圖 1）","url":"https://drugnews.com.tw/assets/articles/2026-q2/dcard-01.webp"},{"alt":"Dcard 原圖：生技人必須知道的 2026 Q2 重磅藥物（圖 2）","url":"https://drugnews.com.tw/assets/articles/2026-q2/dcard-02.webp"},{"alt":"Dcard 原圖：生技人必須知道的 2026 Q2 重磅藥物（圖 3）","url":"https://drugnews.com.tw/assets/articles/2026-q2/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/2026-q2/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-16）。生技人必須知道的 2026 Q2 重磅藥物。https://drugnews.com.tw/articles/2026-04-16-2026-q2.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-16-2026-q2-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}